No Data
CHAMPIONSCI(02509) rose 6.97%. Together with huadong medicine, they are conducting clinical and non-clinical research and registration related work on the target product QX005N.
Jingu Finance News | Quanxin Biotechnology (02509) rose more than 8% intraday, and as of press time, it rose 6.97%, to HKD 21.5, with a turnover of HKD 1.86 million. On the news front, the company announced that on July 19, 2024, it had entered into a cooperation agreement with huadong medicine's (000963) wholly-owned subsidiary, Zhongmei Huadong, on the co-development of clinical and non-clinical studies and registration related work for the symbol product QX005N. The announcement stated that if Zhongmei Huadong exercises its option, it will be responsible for the marketing and promotion of the symbol product in the authorized region, while the company will be responsible for the supply and quality of the symbol product and clinical trial samples.
Hong Kong stocks have changed | Qunxin Biotech-B (02509) rose more than 3% and reached a strategic cooperation agreement with Huadong Medicine on QX005N injection.
Quanxin Biotech-B (02509) rose more than 3%, as of press time, up 3.48%, and reported 20.8 Hong Kong dollars, with a turnover of 1.0786 million Hong Kong dollars.
Qyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N
Qyuns Therapeutics Subscribes to Two Wealth Management Products From Shanghai Pudong Development Bank
HK Stock Announcement: Yankuang Energy plans to cooperate strategically with Highland Resources, which may become the largest shareholder of Highland Resources and acquire control.
Emperor Int'l (00163) plans to sell non-core investment properties in Hong Kong for 1.1547 billion Hong Kong dollars; APEX-BIO (02509) has signed a cooperation agreement with China-US East for the development and potential commercialization of QX005N.
China Traditional Chinese Medicine-B(02509.HK): Collaborating with Sino-America Hua Dong on the development and potential commercialization of QX005N.
On July 21st, Gelonghui announced that Quanxin Biological-B (02509.HK) has signed a cooperation agreement with a wholly-owned subsidiary of huadong medicine (000963.SZ) named China-US huadong on July 19th, 2024. Accordingly, the company grants China-US huadong (i) exclusive joint development rights of the target product in the authorized region and authorized field, (ii) exclusive market promotion selection rights ("selection rights"), and (iii) priority of the transferee of the marketing license holder. The target product QX005N is an anti-IL-4Rα monoclonal antibody (mAb), which has obtained seven items.
No Data
